Anticoagulants oraux après arthroplastie totale de hanche : la problématique de l’observance

Geerts, 2008, Prevention of venous thromboembolism: American college of chest physicians. Evidence-based clinical practice guidelines (8th edition), Chest, 133, 381S, 10.1378/chest.08-0656 Mismetti, 2005, Thromboprophylaxis in orthopedic surgery and traumatology, Ann Fr Anesth Reanim, 24, 871, 10.1016/j.annfar.2005.06.007 Samama, 2007, Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study, J Thromb Haemost, 5, 2360, 10.1111/j.1538-7836.2007.02779.x Laporte, 2003, Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial, Thromb Haemost, 89, 458, 10.1055/s-0037-1613374 White, 1998, Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty, Arch Intern Med, 158, 1525, 10.1001/archinte.158.14.1525 Wolowacz, 2009, Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery, Clin Ther, 31, 194, 10.1016/j.clinthera.2009.01.001 Bellamy, 2010, L’observance thérapeuthique : mesurer, comprendre, intervenir, Rev Chir Orthop, 96, 8 Folstein, 1975, « Mini-mental state ». A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6 Bellamy, 2009, Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate, Patient Prefer Adherence, 3, 173 Ruddy, 2009, Patient adherence and persistence with oral anticancer treatment, CA Cancer J Clin, 59, 56, 10.3322/caac.20004 Kulkarni, 2006, Long-term adherence with cardiovascular drug regimens, Am Heart J, 151, 185, 10.1016/j.ahj.2005.02.038 Dujardin, 2010, L’adhésion du patient à son traitement, une difficulté thérapeutique méconnue, Rev Chir Orthop Traumatol, 96, 1018 Parienti, 2008, Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels, PLoS One, 3, e2783, 10.1371/journal.pone.0002783 Kimmel, 2007, The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (IN-RANGE) study, Arch Intern Med, 167, 229, 10.1001/archinte.167.3.229 Simpson, 2006, A meta-analysis of the association between adherence to drug therapy and mortality, BMJ, 333, 315, 10.1136/bmj.38875.675486.55 Claxton, 2001, A systematic review of the associations between dose regimens and medication compliance, Clin Ther, 23, 1296, 10.1016/S0149-2918(01)80109-0 Vielpeau, 2009, Antithrombotic prophylaxis after THA and TKA: the surgeon's point of view, Ann Fr Anesth Reanim, 28, S29, 10.1016/S0750-7658(09)72462-1 Eikelboom, 2001, Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials, Lancet, 358, 9, 10.1016/S0140-6736(00)05249-1 Eriksson, 2011, Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial, Thromb Haemost, 105, 721, 10.1160/TH10-10-0679 Mismetti, 2009, Fondaparinux 1.5mg in patients with moderate to severe renal impairment undergoing major orthopedic surgery: the Propice study, J Thromb Haemost, 7 Dahl, 2010, A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty, J Thromb Haemost, 8, 1966, 10.1111/j.1538-7836.2010.03965.x Eriksson, 2007, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, Lancet, 370, 949, 10.1016/S0140-6736(07)61445-7 Barrellier, 2010, Short versus extended thrombo-prophylaxis after total knee arthroplasty: a randomised comparison, Thromb Res, 126, 298, 10.1016/j.thromres.2010.07.018 Stangier, 2009, Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, Clin Appl Thromb Haemost, 15, 9S, 10.1177/1076029609343004 Eriksson, 2007, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, J Thromb Haemost, 5, 2178, 10.1111/j.1538-7836.2007.02748.x Samama, 2002, Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant, Arch Intern Med, 162, 2191, 10.1001/archinte.162.19.2191 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638